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Background: Survival benefit from surgical debulking of ovarian cancer (OC) is well established, but some women, despite total
macroscopic clearance of disease, still have poor prognosis. We aimed to identify biomarkers to predict benefit from conventional
surgery.
Methods: Clinical data from women debulked for high-stage OC were analysed (Hammersmith Hospital, London, UK; 2001–2014).
Infinium’s HumanMethylation27 array interrogated tumour DNA for differentially methylated CpG sites, correlated to survival, in
patients with the least residual disease (RD; Hammersmith Array). Validation was performed using bisulphite pyrosequencing
(Charite´ Hospital, Berlin, Germany cohort) and The Cancer Genome Atlas’ (TCGA) methylation data set. Kaplan–Meier curves and
Cox models tested survival.
Results: Altogether 803 women with serous OC were studied. No RD was associated with significantly improved overall
survival (OS; hazard ratio (HR) 1.25, 95% CI 1.06–1.47; P¼ 0.0076) and progression-free survival (PFS; HR 1.23, 95% CI 1.05–1.43;
P¼ 0.012; Hammersmith database n¼ 430). Differentially methylated loci within FGF4, FGF21, MYLK2, MYLK3, MYL7, and
ITGAE associated with survival. Patients with the least RD had significantly better OS with higher methylation of
MYLK3 (Hammersmith (HR 0.51, 95% CI 0.31–0.84; P¼ 0.01), Charite´ (HR 0.46, 95% CI 0.21–1.01; P¼ 0.05), and TCGA (HR 0.64,
95% CI 0.44–0.93; P¼ 0.02)).
Conclusions:MYLK3 methylation is associated with improved OS in patients with the least RD, which could potentially be used to
determine response to surgery.
Ovarian cancer (OC) is the most lethal gynaecological malignancy,
causing over 125 000 deaths per year worldwide (Sankaranarayanan
and Ferlay, 2006). Overall survival (OS) is poor due to late
presentation, poor surgical outcomes, and the development of
chemotherapy resistance. The disease is clinically and molecularly
heterogeneous but despite this all patients are treated the same,
with cytoreductive surgery and platinum-based chemotherapy
(NICE, 2011).
Surgical effort is one of the most important prognostic factors in
OC (Agarwal and Kaye, 2003). It is widely accepted that size of
residual disease (RD) following surgery influences OS following
treatment (Pomel et al, 2008; Shih and Chi, 2010). Five-year OS
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has been shown to improve from 23.9 to 54.6 months in women
having surgical resection to no macroscopic RD vs RD410mm
(Wimberger, 2010). As surgical expertise and effort have improved
total macroscopic clearance rates, it has become apparent that
some patients still respond poorly to treatment, despite complete
removal of all macroscopic tumour at primary surgery.
Gene expression signatures are associated with different survival
outcomes in high-grade serous OC (HGSOC) patients (Tothill
et al, 2008; TCGARN, 2011). Prognostic biomarkers associated
with survival in HGSOC have been widely investigated in the
literature (Fiegl et al, 2008; Flanagan et al, 2013). Notable examples
include overexpression of individual genes such as VEGF, HER2
and progesterone receptor, which have been associated with
progression-free survival (PFS) and OS (Yu et al, 2013; Zhao et al,
2013). Differential DNA methylation at CpG sites, particularly at
CpG islands in gene promoter regions, is also associated with PFS
and OS of HGSOC patients (Dai et al, 2011, 2013; Wang et al,
2014; Chou et al, 2015). These findings improve our understanding
of specific tumour biology and raise the possibility of utilising these
biological characteristics to allow patient stratification to treat-
ment. Differential methylation of O-6-methylguanine-DNA
methyltransferase is already in use clinically to stratify treatment
in those with malignant glioblastomas (Hegi et al, 2005;
Malmstrom et al, 2012; Gupta et al, 2015).
To our knowledge there are no current biomarkers that can be
used to identify women with HGSOC who do poorly despite
optimal surgical treatment (Borley et al, 2012). Thus, there is a
proportion of these patients who undergo maximal effort radical
surgical treatment, with all of the associated potential morbidity
and mortality, without the associated survival benefit. For women
who have a poor prognosis, despite maximal surgical reduction in
disease, alternative therapeutic approaches would need to be
applied in a context of individualised surgical treatment.
The aim of this study was to identify the proportion of women
that have poor prognosis despite maximal surgical effort. Also we
aimed to identify and validate potential DNA methylation
biomarkers, which may enable stratification of care to different
surgical and treatment pathways. DNA methylation as a biomarker
was selected due to its relative stability ex vivo and in vivo, as well
as the future potential to detect DNA methylation changes non-
invasively in circulating tumour DNA (Keeley et al, 2013;
Bettegowda et al, 2014). As the success of surgical debulking is
associated with the ability of tumour cells to invade and
metastasise, we focused on the ‘focal-adhesion’ and ‘adherens-
junction’ pathways, involved with cell surface adhesion, and the
‘regulation of actin cytoskeleton’ pathway involved with cell
migration (Laboratories, 2013).
PATIENTS AND METHODS
This proposal was reviewed and agreed by the ‘HTA-approved’
Imperial College Healthcare NHS Trust Tissue Bank (authorised
by the Wales MREC) project reference Gyn_HG_12_060 and
Gyn_HG_13_020. Written consent was obtained from all patients
included in this study who provided tumour tissue for research.
Reporting recommendations for tumour marker (REMARK)
criteria were followed throughout this study.
Historical Hammersmith database. Electronic patient records
from January 2001 to December 2014 at Hammersmith Hospital,
Imperial College Healthcare NHS Trust (ICHNT; West London
Gynaecology Oncology Surgical Centre) were searched to identify
cases. Inclusion criteria were primary serous ovarian, fallopian, or
peritoneal carcinoma (mixed tumours were included if the
epithelial component predominated), stage 3/4, and primary
surgical debulk was initial treatment. Staging was classified using
the version of International Federation of Gynaecology and
Obstetrics staging classifications in place at the time of diagnosis.
OS and PFS were determined from the date of surgery until the
date of the event (death or recurrence/progression, respectively) or
last known contact. All survival data were updated between 15 June
2015 and 03 July 2015. If patients were lost to follow-up they were
censored accordingly. RD status was classified as total debulking
(0mm RD), optimal debulking (RD p10mm), and suboptimal
debulking (410mm RD).
Patient tumour samples. Fresh-frozen OC tissue was collected
and stored at  80 1C by ICHNT Biobank London and Tumour
Bank Ovarian Cancer (TOC) (www.toc-network.de) at Charite´
Hospital Berlin. Tumours were derived from primary debulking
surgery and were stage 3/4 serous histology. Tumour sample
quality was ensured by histopathology (excluded if tumour cell
nucleio20%). Overall survival and PFS were determined from the
date of surgery until the date of the event (death or progression,
respectively) or last known contact and censored if lost to follow-
up. The Hammersmith and TOC-Charite´ DNA methylation data
sets included serous tumour with similarly matched age and stage.
Residual disease differed between the data sets, with suboptimal
debulking rates lower in the TOC-Charite´ and The Cancer
Genome Atlas (TCGA) data sets compared to Hammersmith.
This may reflect the significant variability between surgeons’
approach to radicality, skills, and the significant difficulty in the
reproducibility of tumour measurements, which corresponds with
previously described variability among surgical expertise and
outcomes among different centres and different countries (Chi
et al, 2009; Vergote et al, 2010). The potential effect this may have
on survival was mitigated by adjusting for RD as a confounder. Of
all patients that were fit to have chemotherapy, over 95% received
platinum-based chemotherapy.
TCGA data set. Publicly available clinical, surgical, methylation,
and expression data for patients with serous cystadenocarcinoma
were downloaded from TCGA data portal (https://tcga-data.nci.
nih.gov/tcga/; TCGARN, 2011). Methylation data were obtained
using 27k and 450k Illumina Infinium (San Diego, CA, USA)
methylation arrays. We included 277 patients with stage 3/4
disease. Supplementary Table S1 shows the clinical characteristics
of the historical Hammersmith database cases and the three
independent methylation data sets.
Tumour DNA extraction and bisulphite conversion. Up to
500mg of tumour tissue was used per sample, and DNA was
extracted using the chlorinated Nucleon extraction (GE Healthcare
Life Sciences, Buckinghamshire, UK) method. Tumour DNA was
bisulphite-converted with EZ-96 DNA Methylation Kit (Zymo,
Irvine, CA, USA) as per the manufacturer’s protocol. A unit of 1 mg
of genomic DNA was used for each sample.
Illumina Infinium HumanMethylation27 beadchip array.
Discovery-set samples (Hammersmith array data set) were processed
as per the Infinium Assay Methylation Protocol (Illumina). A unit of
200 ng of genomic DNA was used for bisulphite conversion.
Methylation data were summarised as b-values, calculated as
M/(MþU), where M is the signal from methylated beads and U is
the signal from unmethylated beads at the targeted CpG site. b-values
were adjusted against background noise and data were log-
transformed to achieve a normal distribution. Probes with a detection
P-value of 40.05 were removed. Quality control checks were
performed with GenomeStudio (Illumina).
Pyrosequencing. DNA methylation of the validation-set samples
(TOC-Charite´ data set) was determined through PCR amplifica-
tion with biotinylated primers (Invitrogen Life Sciences, Carlsbad,
CA, USA; and Sigma Aldrich, St Louis, MO, USA) using Pyromark
Assay Design Software version 2.0 (Supplementary Table S2), and
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Qiagen (Hilden, Germany) Pyromark Q96 MD pyrosequencer as
previously described (Dai et al, 2013). Amplified products were
confirmed with agarose gel electrophoresis. Pyro-Q-CpG (Qiagen)
software was used to calculate CpG site methylation values using
the same M/(MþU) calculation as with the beadchip array.
Statistical analysis. Analysis was performed using R v3.2.2.
Univariate analyses using the log-rank test were performed and
corresponding log-rank P-values reported. The OS and PFS
analyses were plotted using Kaplan–Meier survival curves. Patients
lost to follow-up were censored and their last known contact used
for survival purposes. Multivariable adjustment was performed for
true confounders, including age, stage, grade, RD status, and batch
using Cox proportional hazards models and shown as multi-
variable Cox P-values. Hazard ratios (HR) and 95% confidence
intervals (95% CIs) are reported alongside the Cox P-values.
Statistical significance was set at Po0.05.
RESULTS
Changing surgical trends towards more radical surgery are
associated with improved survival. Over the past 15 years,
surgical trends have moved towards a more radical approach in
response to mounting evidence of prognostic benefit with reduced
tumour burden (Chi et al, 2009). To evaluate this trend at
Hammersmith Hospital and to establish whether this impacted
upon survival, debulking rates were compared year by year and
survival of these patients was evaluated using Kaplan–Meier
survival curves; Figure 1. In 2013 and 2014, less than a quarter of
patients had any measurable disease left after surgery, compared
with over 75% in 2001–2003 (Figure 1A). A total of 430 women
who underwent primary debulking surgery were included in the
analyses. The survival curves in Figure 1B and C show statistically
significant OS (HR 1.25, 95% CI 1.04, 1.47) and PFS (HR 1.23, 95%
CI 1.05, 1.43) advantage for women with the least RD after surgery.
Median OS for patients with RD410mm was 13.2 months,
compared to those with zero RD with median OS of 26.2 months.
Median PFS (Figure 1C) improved with reducing RD as expected.
Despite patients receiving total macroscopic clearance, it is clear
that some of these patients, even with maximal surgical effort, do
poorly with respect to survival. Of all totally debulked (0mm RD)
patients in the Hammersmith database, 8.8% died within 12
months of their surgery. Median OS in this group of women was
only 3 months (inter-quartile range 0.5–8.0 months). These
patients may not have benefitted from extensive surgery and
may have potentially benefitted from alternative treatment
strategies, highlighting the need for a robust biomarker to identify
these women. We therefore used three independent tumour DNA
data sets to identify and validate DNA methylation biomarkers
associated with survival in patients with the least RD.
DNA methylation biomarkers predict poor survival in optimally
debulked patients. To identify differential methylation associated
with survival in optimally debulked patients, DNA methylation of
tumour DNA determined through Illumina’s Infinium Human-
Methylation27 BeadChip array was investigated (Hammersmith
array data set). Multivariable Cox proportional hazards models were
performed on optimally debulked patients only. The Kyoto
Encyclopaedia of Genes and Genomes was used to identify 732
methylation probes covering genes involved with adhesion and
migration pathways. Our hypothesis was that genes involved in this
pathway could affect survival by increasing metastatic potential and
tumour invasiveness, therefore leading to biologically more
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Figure 1. Surgical trends and survival according to debulk status in the Hammersmith Database between 2001 and 2014. (A) Debulk rates
(percentage of all cases) at Hammersmith Hospital between 2001 and 2014. Total macroscopic debulk (0mm RD) shown in black, optimal debulk
(RD 1–10mm) in red, and suboptimal debulk (RD410mm) in green. (B) Overall survival – total debulk vs suboptimal debulk (HR¼ 1.25 (95% CI
1.06, 1.47)). (C) Progression-free survival – total debulk vs suboptimal debulk (HR¼ 1.23 (95% CI 1.05, 1.43)). Multivariable Cox proportional
hazards model adjusting for age, stage, grade, and histology.
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aggressive tumours. The hypothesis-driven analysis was performed
on 732 loci and 65 were found to show differential methylation
associated with OS (Po0.05). To increase the likelihood of detecting
clinically relevant differential methylation we chose a differential
methylation cut-off of 20%. Consequently, 36 probes were included
in further analysis. Cox proportional hazards models were used to
adjust for age, stage, chip, and RD to investigate whether patients
had different survival distributions per locus. Of the 36 loci, 27 were
found to be significant (Supplementary Table S3). The six probes
with the largest effect size, FGF4, FGF21,MYLK2, myosin light chain
kinase 3 (MYLK3), MYL7, and ITGAE are shown in Table 1, and
were taken forward for validation.
MYLK3 CpG locus methylation predicts poor outcome in
patients with the least RD. Validation of the six significant loci
associated with survival in the Hammersmith Array data set was
performed using an independent data set (TOC-Charite´). DNA
methylation of all six loci in OC tumour DNA was quantified by
bisulphite pyrosequencing of the TOC-Charite´ data set validation
cohort. As there was a low number of suboptimally debulked
patients in this group (n¼ 6), total debulk (n¼ 47) was compared
to any amount of RD (n¼ 36). MYLK3 was the only locus to
validate in TOC-Charite´ (P¼ 0.025; Figure 2B). The same analysis
was performed in TCGA data set for all six discovery loci
(Supplementary Table S4). Although MYLK3 did not quite reach
significance (P¼ 0.06), in the TCGA analysis there is a clear trend
in the survival curves (Figure 2A–C) towards improved survival
with increased methylation of MYLK3 in all data sets. Survival for
patients with low methylation appears to be comparable to that of
their suboptimally debulked counterparts, who had significant RD.
Patients appeared not to benefit from the radical surgery in the
same way their highly methylated counterparts did.
Further multivariable analysis focused only on patients with the
least RD, as clinically it would be beneficial to be able to predict
Table 1. Six most significant differentially methylated loci in
Hammersmith discovery cohort using 27k methylation array
associated with survival in patients with the least residual
disease (optimal debulk n¼39)
Probe ID
Gene
name
Median
methylation
%
Cox
model
(P)a HR 95% CI
cg14578030 FGF4 85.2 0.011 0.39 0.19, 0.81
cg21856603 ITGAE 77.5 0.042 0.48 0.24, 0.98
cg16155702 FGF21 74.3 0.031 0.50 0.26, 0.94
cg13247990 MYLK3 80.1 0.008 0.51 0.31, 0.84
cg19961522 MYLK2 73.2 0.024 0.57 0.35, 0.93
cg23370883 MYL7 61.7 0.026 0.57 0.35, 0.94
Abbreviations: CI¼ confidence interval; FGF4¼ fibroblast growth factor 4; FGF21¼
fibroblast growth factor 21; HR¼ hazards ratio; ITGAE¼ integrin alpha E; MYLK2¼myosin
light chain kinase 2; MYLK3¼myosin light chain kinase 3; MYL7¼myosin light chain 7,
regulatory.
aP-value determined by Cox proportional hazards model adjusting for age, stage, chip, and
residual disease status. Supplementary Table S3 lists the multivariable Cox proportional
hazards survival analysis for the top 27 significant probes.
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Figure 2. Kaplan-Meier overall survival curves according to debulk status and methylation (metn), shown as higher or lower than the median
methylation for all patients. (A) Probe cg13247990 on 27k methylation array in discovery cohort (Hammersmith Array data set) with debulk status
shown as ‘optimal’ vs ‘suboptimal’. (B) Pyrosequencing of MYLK3 locus in validation cohort (Charite´ data set) with debulk status shown as ‘total’
debulk vs any ‘residual’ disease. (C) Probe cg13247990 on methylation array in TCGA data set with debulk shown as ‘optimal’ vs ‘suboptimal’.
(D) Hammersmith patients with optimal debulk (HR¼0.51 (95% CI 0.31, 0.84). (E) Charite´ patients with total debulk (HR¼ 0.46 (95% CI 0.21, 1.01)).
(F) TCGA patients with optimal debulk (HR¼0.64 (95% CI 0.44, 0.93). *All multivariable analyses adjusted for confounders age and stage plus
grade, chip, and RD status when appropriate.
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which patients would benefit most from radical surgery. Differ-
ential methylation survival analysis of the MYLK3 locus was
conducted in the Hammersmith and TOC-Charite´ data sets, as
well as TCGA data set (Table 2 and Supplementary Table S4).
Higher methylation of the MYLK3 locus is associated with OS in
patients with the least RD in all three independent cohorts of
patients (Figure 2D and E), however the TOC-Charite´ data set was
borderline significant (P¼ 0.053).
The optimally debulked Hammersmith patients with higher
methylation at the MYLK3 locus had median OS of 52.4 months,
falling to 33.0 months in patients with lower methylation. Patients
with higher methylation in TCGA data set had median OS of 44.5
months, a survival advantage of 10.5 months when compared to
median OS of the low-methylation group, which was 34.0 months.
Charite´ patients had the largest survival advantage from higher
methylation in their totally debulked patients with median OS of
68.0 months with higher methylation, falling to 34.7 months in the
lower-methylation group. On average, women with higher
methylation of the MYLK3 locus appear to have 10.5–33.2 months’
additional OS advantage across the three independent cohorts in
this study. The TOC-Charite´ result may reflect that the effect of
higher methylation at MYLK3 is most profound in patients with
total macroscopic clearance of their disease. To further investigate
this theory, all three methylation data sets were combined, totalling
436 women for analysis in a similar manner to the TOC-Charite´
and TCGA validation analyses. The combination of all data
sets increases the numbers of patients in all subgroups and
enables an analysis of the entire cohort splitting the groups
into ‘total macroscopic clearance of disease’ and ‘any RD’.
Potential batch effects, combining these data sets, were adjusted
for in the multivariable Cox model for this analysis as an indicator
variable. Figure 3 shows a highly significant association (log-rank
P¼ 4.33e 7, Cox P¼ 0.0040, HR 0.67, 95% CI 0.51, 0.88) between
OS and methylation of MYLK3, most prominently in totally
debulked patients. Patients with any RD also appear to gain
significant survival benefit by having higher methylation of
MYLK3. The protective benefit of higher MYLK3 methylation
pulls the survival curve for the RD group into a similar position to
the totally debulked patients with low methylation and appears to
be a protective factor itself.
Expression of MYLK3 is not directly linked to survival or
methylation of the MYLK3 locus. Hammersmith and TOC-
Charite´ data sets did not have matched expression data, so TCGA
expression data set was interrogated separately. All 277 patients in
TCGA data set who had methylation data had matched expression
data for MYLK3. Potential correlation between methylation and
expression was investigated with Spearman’s rank correlation test
(Figure 4A). There was no significant correlation between
methylation of the MYLK3 locus and expression of the MYLK3
gene (P¼ 0.55, r¼  0.042). Furthermore, there was no statisti-
cally significant association between expression of the gene and OS
(log-rank P¼ 0.143, Cox P¼ 0.152; Figure 4B). The same analysis
was also performed on the other five discovery genes, all of which
similarly showed no association with survival (data not shown).
DISCUSSION
Currently, all patients with advanced stage OC are treated with
surgery and chemotherapy, despite our expanding knowledge of
the heterogeneity of the disease. The benefit of achieving total
macroscopic clearance of disease is now well recognised and these
data show that this has served patients well in the past, as survival
is significantly improved by performing increasingly radical
surgery. However, although this blanket approach improves
survival across a population, it takes no account of individual
tumour biology and therefore is not necessarily the best treatment
for all patients. Increasingly, more is known about the biology of
tumours, chemotherapy evasion, the development of resistance,
and the process of metastasis: future treatments will increasingly be
focused on exploiting these unique characteristics. In the new age
of personalised medicine, where patients should expect to have
their care tailored for their individual needs, it is essential to
determine biomarkers that will allow the stratification of care and
to truly personalise medicine. Surgical biomarker studies tend to
have poor surgical annotations, and most studies are limited by
heterogeneous samples and lack adjustment for major confounding
factors (Borley et al, 2012). Clinical, histological, and surgical
Table 2. Six candidate loci validation analysis in the Charite´
cohort using bisulphite pyrosequencing of differentially
methylated loci associated with survival in patients with the
least residual disease (total debulk n¼47)
Probe ID
Gene
name
Median
methylation
%
Cox
model
(P)a HR 95% CI
cg14578030 FGF4 92.2 0.355 0.68 0.30, 1.55
cg21856603 ITGAE NA NA NA NA
cg16155702 FGF21 78.4 0.064 0.44 0.18, 1.05
cg13247990 MYLK3 86.3 0.053 0.51 0.21, 1.01
cg19961522 MYLK2 90.5 0.998 1.00 0.43, 2.30
cg23370883 MYL7 77.0 0.224 0.59 0.26, 1.38
Abbreviations: CI¼ confidence interval; FGF4¼ fibroblast growth factor 4; FGF21¼
fibroblast growth factor 21; HR¼ hazards ratio; ITGAE¼ integrin alpha E; MYLK2¼myosin
light chain kinase 2; MYLK3¼myosin light chain kinase 3; MYL7¼myosin light chain 7,
regulatory; NA=not available. ITGAE results not available as pyrosequencing assay failed.
aP-value determined by Cox proportional hazards model adjusting for age, stage, and
grade.
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Figure 3. Overall survival in all three data sets combined. Overall
survival significantly improved by reducing RD and increasing MYLK3
methylation. Survival benefit from total debulk appears to be lost in the
presence of low methylation of MYLK3. Similarly, women with RD gain
survival from having high MYLK3 methylation. Total of 436 women
included from Hammersmith, Charite´, and TCGA data sets. Survival
dichotomised by median methylation of MYLK3 derived from the total
cohort (84.9%) and debulk status. *Multivariable model adjusted for
age, stage, grade, debulk, batch, and an integer variable to adjust for
combining data sets.
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annotations in this study were collected to a very high standard,
mitigating some of the limitations inherent in previous surgical
biomarker research.
MYLK3 is a protein-coding gene found on chromosome 16
(16q11.2) recognised for its role in the regulation of actin
cytoskeleton and immune response signalling. It phosphorylates
cardiac myosin heavy (MYH7B) and light (MYL2) chains,
potentiating the force and rate of cross bridge recruitment in
myocytes (Chan et al, 2008). Also, myosin light chain kinases have
been linked to the regulation of epithelial cell survival, and
knockdown of the gene has led to apoptosis of epithelial breast line
cells in vitro (Connell and Helfman, 2006). Myosin light chain
kinase on chromosome 3, has a role in epithelial tight junction
permeability, has been shown to be a warning marker for gastric
cancer and has also been shown to promote cell proliferation
(Al-Sadi et al, 2008; Han et al, 2011; Chen et al, 2012). It is not
clear why differential methylation at this CpG locus in MYLK3
seems to affect OS in patients who have received maximal surgical
effort. Our findings may represent the OC cells’ ability to invade
their basement membrane, move across epithelial junctions, and/or
have a role in metastasis. To our knowledge there is no current
evidence showing any association between DNA methylation of the
MYLK3 gene promoter region and expression of the gene. Nor is
there any literature linking MYLK3 to OC outcomes. Differential
CpG island methylation is often associated with gene expression,
but MYLK3 does not contain a regulatory CpG island in its
promoter region. Differential methylation can however affect a
locus outside a CpG island by influencing transcription factor
binding (Medvedeva et al, 2014). The locus examined here sits
within the promoter region of the gene, only 45 base pairs from the
transcription start site, but not as part of a CpG island. It is
therefore not likely that methylation at the locus would have a
direct effect on expression of MYLK3 specifically. An alternative
hypothesis is that methylation at this locus could be a surrogate
marker for effects on the transcription of other genes. Further work
should be performed to establish the exact nature, cause, and effect
of this differential methylation on OC survival. In the meantime,
differential methylation at the cg13247990 MYLK3 locus appears
to have significant potential as a surgical biomarker, which may
enable stratification of surgical care according to the biology of
patients’ tumours. The MYLK3 biomarker could potentially be
measured from tumour biopsy samples or from cell-free circulating
tumour DNA (Bettegowda et al, 2014). Those patients with
high methylation appear to have the best outcome from total
macroscopic debulking and could therefore be assigned the most
radical surgery. Women with low methylation may not benefit
from radical upfront surgery, and other treatment strategies
may be more beneficial, including the consideration of neo-
adjuvant chemotherapy. Clearly, the potential benefits of our
findings would need to be confirmed in an appropriately controlled
clinical trial.
In the Hammersmith database cohort of 430 women, 8.8% of
totally debulked patients had progressed or died within 12 months
of surgery, with very poor median OS of 3 months. It is
questionable how much benefit these women received from radical
surgery and our conventional treatment approaches. Differential
methylation of MYLK3 could potentially have an exciting part in
the future of personalised medicine in OC surgery. The ability to
determine which women will respond well to radical surgery would
be a significant advancement in the treatment of OC.
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